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Abstract
Invasive fungal infections are major causes of morbidity and mortality in neonates and in both immunocompromised and immunocompe-
tent children. Although these infections have been well characterized in adults, the incidence and analysis of risk factors, diagnostic
tools, treatments and outcomes have not been well described for large cohorts of paediatric or neonatal patients. Paediatric exclusion
has limited our knowledge of the epidemiology and pathophysiology of paediatric fungal disease, and has also resulted in a paucity of
data regarding the safety and efﬁcacy of paediatric antifungal therapy. Previous paediatric cooperative models in other disciplines have
successfully advanced our understanding and treatments of childhood diseases, but in the past there has not been a similar organization
for paediatric invasive fungal infections. Although there are numerous other reviews outlining the differences in paediatric antifungal dos-
ing pharmacokinetics, there are only smaller epidemiological reports depicting the exact distribution and outcomes of paediatric invasive
fungal infections treated with these antifungals. This review will highlight some of the available epidemiological data on paediatric invasive
fungal infections.
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Introduction
Epidemiology is at the heart of medicine. Detailed epidemiol-
ogy allows us to understand which patients will become sick
and why, letting us determine who is at risk for developing
disease and therefore better direct our diagnostic and thera-
peutic efforts as well as more accurately predict prognosis.
Invasive fungal infections are major causes of morbidity and
mortality in both the expanding immunocompromised and
the immunocompetent patient populations [1]. As contem-
porary medicine advances the treatment of life-threatening
conditions such as malignancies, organ transplantation, and
autoimmune disorders, invasive fungal infections have
become a major complication. Candida species constitute the
fourth most common pathogen isolated in nosocomial blood-
stream infections [2]. Cryptococcal meningitis caused by
Cryptococcus neoformans and Cryptococcus gattii is the most
common cause of fungal central nervous system infection in
the world today, primarily producing disease in immunocom-
promised patients, but also causing disease in apparently nor-
mal hosts [3]. The incidence of invasive aspergillosis (IA)
caused by Aspergillus fumigatus has increased three-fold in the
last decade [4], and IA mortality has correspondingly risen
by over 300% [5]. The Infectious Diseases Society of Amer-
ica listed A. fumigatus as one of only six infectious pathogens
for which a substantive treatment breakthrough is urgently
needed [6].
Effective treatments for invasive fungal infection-associated
morbidity and mortality are often lacking. Treatment for
invasive candidiasis and cryptococcal meningitis has an
approximately 70% success rate, but generally only in the
healthiest patients [7,8]. Current therapy for IA has a disap-
pointing 40–50% treatment success rate [9,10]. The poor
therapeutic outcomes of invasive fungal infections, coupled
with expensive underlying endeavours such as transplanta-
tion and intensive-care unit management, mean that both
the human and the ﬁnancial costs of invasive fungal infections
are exceedingly high. The burden of invasive fungal infections
on the healthcare system is staggering, with conservative
estimates of $2.6 billion annually in the USA alone [11]. In
many major medical centres, antifungals currently comprise
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the largest proportion of overall anti-infective expenditure
[12].
This review will focus on some of the epidemiology of
paediatric invasive fungal infections, information that we can
use to guide current diagnosis as well as design future thera-
peutic trials in the ﬁeld. The focus will be on the major inva-
sive fungal infections, IA and invasive candidiasis in children
and neonates. Although many aspects of risk factors and
treatment algorithms learned over the last several decades
from adult patients can be employed in children, there are
some unique nuances in children that are outlined for the
practising clinician.
Paediatric and Neonatal Epidemiological
Factors
Autopsy data demonstrate that IA has surpassed invasive
candidiasis as the most frequent invasive fungal infection in
some tertiary medical centres [13–18]. The treatment suc-
cess rate with IA remains approximately 50%, despite newer
antifungals now being available [9]. Despite the increasing
incidence and continued dismal outcomes, the majority of
information on IA epidemiology, diagnosis, treatment and
outcome has been obtained from studies conducted almost
solely on adult patients. Each clinical trial for IA has purpose-
fully excluded children, and some have enrolled a small num-
ber of patients older than 12 years. There have been several
previous paediatric IA epidemiology reports, but most were
only single-centre studies and conducted prior to the avail-
ability of many newer antifungals and diagnostic strategies.
Similarly, although IA has been shown to be the most deadly
of the frequently occurring invasive fungal infections [19],
invasive candidiasis is generally known as the most common
invasive fungal infection among immunocompromised
patients. However, although there are have been great
strides in understanding the high-risk groups and outcome
data in adult patients with candidiasis, children have been
neglected in large-scale analyses.
The largest multicentre, prospective analysis of paediatric
IA included 139 contemporary cases from six US medical
centres [20] in the setting of newer diagnostic and therapeu-
tic tools. The mean age of patients was 9.9 years, and the
majority of the patients had an underlying malignancy. An
equal number of patients had underlying malignancy not trea-
ted with haematopoietic stem cell transplantation (HSCT) or
an underlying disorder treated with HSCT. Most patients
had numerous immunosuppressive risk factors in the 30 days
prior to diagnosis of IA, including neutropenia (Absolute
neutrophil count (ANC) <500/mm3) for ‡3 days in 59% of
the patients, and in approximately 30% of these the neutro-
penia lasted for ‡30 days (overall mean 18.9 days). Concomi-
tant infections consisted of 124 episodes of bacterial, viral
and other fungal infections among 65.5% of the patients, of
which bacterial infections accounted for approximately half
of all the concomitant infections.
A second paediatric IA study was a prospective, 5-year
observational study in 346 paediatric cancer patients receiv-
ing intense chemotherapy for newly diagnosed or recurrent
malignancy at the University Hospital of Frankfurt [21]. Dur-
ing the 5-year period, there were 13 cases of IA, and all
cases occurred in patients with haematological malignancy;
the highest rates were seen in patients with acute myeloge-
nous leukaemia (AML) and relapsed acute lymphocytic leu-
kaemia (ALL). This study only looked at patients with
malignancies and found a higher predominance of IA in those
patients with leukaemia than in those with solid tumours.
Similarly, a recent single-centre review from France [22]
found 24 cases from 1986 to 2000, and the greatest inci-
dence of disease was in acute myeloblastic leukaemia (5.35%)
and leukaemic relapse (4%), with survival being only 12.5%.
The largest analysis of high-risk immunocompromised pae-
diatric patients with and without IA found staggering differ-
ences in mortality resulting from IA [23]. Among the
common paediatric malignancies, overall mortality from AML
(3%) and from ALL (1%) was quite low. However, when chil-
dren with these malignancies also developed IA, their mortal-
ity escalated to 20% and 21%, respectively. This equated to
relative risks of mortality of 5.0 in AML patients and 14.9 in
ALL patients, altering paediatric malignancies with high cure
rates to diseases with substantial mortality resulting from IA.
A 49-hospital paediatric study found that Candida species
constituted the fourth most common cause of bloodstream
infection (9%) in children less than 16 years old, following
coagulase-negative Staphylococcus (43%), enterococci (9%),
and Staphylococcus aureus (9%) [24]. The limited data available
show that the Candida species infecting children appear to
differ from those causing adult infections. For instance,
whereas Candida albicans is the most frequently isolated Can-
dida species in both adult and paediatric patients, Candida
parapsilosis is clearly the second leading species in paediatric
patients, whereas Candida glabrata follows in adult patients
[25]. Another study showed similar results, indicating that
the percentage of candidaemia caused by C. parapsilosis was
higher among children <1 year of age (17%) than in all other
age groups (6%). Additionally, the percentage caused by
C. glabrata again steadily increased with age [26]. In addition
to Candida infections in immunocompromised children, it
is becoming increasingly more common to see immuno-
competent children with candidaemia—resulting from either
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long-term central-line placement for nutrition, abdominal or
thoracic trauma, or other intensive-care settings.
Risk factors for neonatal invasive candidiasis include many
of the standard risks that pertain to adult patients, such as
central venous catheter use, acid blockers, and antibacterial
use. However, in the neonates, both incidence and outcomes
are also linked to the gestational age and the birthweight of
the baby. For instance, one study found that a gestation age
of <25 weeks led to an OR of 4.15 for developing candidiasis
as compared with babies ‡28 weeks, whereas a baby with a
gestation age of 25–27 weeks had a lower OR of 2.02 [27].
Other risks in the 7 days prior to infection included throm-
bocytopenia (OR 3.56) and cephalosporin or carbapenem
use (OR 1.77). End-organ dissemination and damage from
candidaemia appears to be much higher in neonates, with a
meta-analysis of 21 studies yielding an average of 49%
patients with candiduria and 16% of neonates with candida-
emia with culture-positive meningitis [28]. Candiduria in neo-
nates was also evaluated prospectively in Canadian nurseries,
and it was found that the most common underlying disorder
was congenital heart disease, and that renal ultrasonography
ﬁndings were present in 58% of those infants with candiduria
[29], highlighting the importance of a full dissemination evalu-
ation in a baby with candiduria. Further neonatal evaluation
found that babies with a birthweight of 400–750 g had an
OR of 3.22 for developing candidaemia as compared with
the already at-risk babies with a birthweight of 751–1000 g.
Importantly, of the babies with meningitis in this cohort of
nearly 5000 babies, 48% had meningitis but negative blood
cultures, despite their concurrent meningitis [30]. Dissemina-
tion to the eyes is also common, with an OR of 7.4 for neo-
nates with candidaemia to require surgery for retinopathy of
prematurity as compared with control matched infants,
including a greater risk for retinal detachment [31].
A prospective neonatal candidiasis study found that,
between 1994 and 1999, C. albicans predominated. However,
between 1999 and 2000, non-albicans species (especially
C. parapsilosis) predominated [32]. The mean day of life of
development of candidiasis was 13.4 days, with 18.6% of the
cases developing within the ﬁrst week of life. In another
study, weekly surveillance fungal cultures were taken from
neonates and 12.1% were colonized with Candida, including
C. albicans in 42% [33]. Most were colonized later (>5 days),
and neonates born vaginally were at higher risk for early col-
onization. Importantly, invasive candidiasis occurred in 6.9%
of colonized neonates, but in only 0.76% of non-colonized
infants, suggesting that monitoring for colonization in the
highest-risk infants may be beneﬁcial. A larger Italian study
[34] found that 32.1% of very low birthweight infants
(<1500 g) were colonized with Candida and infection
occurred in 8.1% of those colonized babies. Following logistic
regression, only colonization of central venous catheters and
colonization at other sites remained signiﬁcant for invasive
fungal infection.
Paediatric and Neonatal Clinical Invasive
Fungal Disease
In the largest analysis of paediatric patients with IA [20],
A. fumigatus was the species most frequently recovered by
culture (52.8%), followed by Aspergillus ﬂavus (15.7%), Asper-
gillus terreus (4.7%), and Aspergillus niger (4.7%). Nodules con-
stituted the most frequent ﬁnding on chest computed
tomography (CT) or plain radiography (59%), and nodules
were seen less frequently in the youngest children than in
the older age groups: nodules were seen in 38.7% (12/31) of
the 0–5-year-olds, as compared with 71.8% (28/39) and
62.5% (25/40) of the 6–12-year group and ‡13-years group,
respectively. Only 3/110 patients (2.2%) showed the air-cres-
cent sign, none of whom were in the 0–5-year age group.
There are conﬂicting reports on a potential Aspergillus spe-
cies difference seen in infected children vs. adult patients. The
National Institute of Allergy and Infectious Diseases Bacteriol-
ogy and Mycoses Study Group reviewed 256 isolates of Asper-
gillus species from adult patients who had IA from 24 medical
centres [35], and A. fumigatus accounted for 67% of the iso-
lates, A. ﬂavus being the second most common isolate, at 16%.
In contrast, the previously described St Jude [36] and Toronto
[37] paediatric reviews revealed that A. ﬂavus was the most
common species isolated. However, in more recent studies,
the paediatric IA epidemiology has paralleled that in adults,
with a 2001 French paediatric study demonstrating that the
most common isolates were A. fumigatus (11/23) and A. ﬂavus
(6/23) [38]. The larger study of contemporary cases [20] mir-
rored the newer French paediatric study and adult ﬁndings
[9,35], suggesting that the earlier claims of A. ﬂavus predomi-
nance in children possibly resulted from older cases of IA.
In adult studies [39], pulmonary IA is the clinical site most
commonly identiﬁed, which is to be expected, given the air-
borne route of infection. In the large multicentre paediatric
series [20], 79.9% of cases were pulmonary IA, and 13.7%
were cutaneous IA. Of the patients with cutaneous disease,
52.6% (10/19) had disease strictly localized to the skin. A. fu-
migatus was the species responsible for 70% (7/10) of these
strictly cutaneous infections, A. ﬂavus and A. niger caused two
of the other infections, and in one case the species was not
identiﬁed. In the Toronto study [37], in 41% (16/39) of the
patients the Aspergillus infection was cutaneous, and in the
St Jude review [36], 20% (13/66) of patients had cutaneous
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infection. However, other paediatric series have not shown
such predominance of primary cutaneous infection, as the
Frankfurt study only reported one such case [21]. In a sys-
tematic review of nosocomial Aspergillus outbreak reports,
53 outbreaks were found, affecting 458 patients. Skin infec-
tions were reported in only 5.2% (24/458) [40]. A paediatric
IA review was conducted at the Hospital for Sick Children in
Toronto, involving 39 cases of paediatric IA from 1979 to
1988 [37]. Cutaneous Aspergillus infection was found in 41%
of the patients, and approximately half had pulmonary infec-
tions. The overall survival rate was 23.1% (9/39). Another
paediatric study was a review of 66 cases of proven IA from
9500 children treated from 1962 to 1996 at St Jude Chil-
dren’s Research Hospital (Memphis, TN, USA) [36]. The
most common site of infection was the lung (70%), and this
was followed by skin lesions (20%) and sinus disease (18%).
The St Jude study did include a more diverse population of
patients, but many of the cases analysed were from over
three decades ago, and may therefore be difﬁcult to extrapo-
late to today’s patients.
The diagnostic features of IA may also be different in chil-
dren [41,42]. In adult series of pulmonary aspergillosis,
approximately 50% of patients show cavitation and 40% have
air-crescent formation [43]. However, in a 10-year review
of 27 consecutive paediatric cases, with a mean age of
5 years (7 months to 18 years), central cavitation of small
nodules was seen in only 25% of children, and there was no
evidence of air-crescent formation within any area of con-
solidation on CT [44]. Another paediatric series with a
higher mean age showed that 43% (6/14) of patients had
cavitation on CT [45]. It may be that air crescent and
cavitation are seen only in the older population of children,
suggesting an underlying difference in pathophysiology in
children. The large multicentre paediatric study showed sim-
ilar ﬁndings to these older paediatric studies and, unlike in
the adult series, cavitation was only seen in a fraction of
paediatric cases of IA.
It is now clear that there are different patterns of Candida
isolates obtained from children than from adults, and the
clinical manifestations also appear to be different. In one
study comparing children and adults with candidaemia, septic
shock and meningitis were statistically more common in chil-
dren than in adults, probably reﬂecting neonatal disease [46].
One observational candidaemia study included 34 tertiary
medical centres from 1995 to 1997, and found survival from
candidaemia to be greater in children (76%) than in adults
(54%, p < 0.001), a fact that may merely reﬂect the general
better health of children than of adults.
Although not the focus of this review, all of these clinical
disease epidemiological factors may contribute to diagnostic
differences between children and adults. In an adult series of
pulmonary aspergillosis, approximately 50% of cases showed
cavitation and 40% air-crescent formation [43]. However, in
one 10-year review of 27 consecutive paediatric patients
(mean age 5 years), there was central cavitation of small
nodules in 25% of children and no evidence of air-crescent
formation within any area of consolidation [44]. In another
paediatric report, there was a 22% (6/27) rate of cavitation
on chest radiography [47], and in another there was a 43%
(6/14) rate of cavitation on CT [45]. In these two paediatric
series, the mean ages were higher than in the report of
lower rates of cavitation and no air-crescent formation, sug-
gesting that there is a spectrum of radiological disease pre-
sentation that is directly related to age.
Whereas diagnosis of paediatric IA with new antigen tests,
such as the galactomannan (GM) assay, initially showed differ-
ences between paediatric and adult patients with respect to
higher false-positive values in children [48,49], more recent
and comprehensive studies have demonstrated that GM test-
ing is effective in children at risk for IA [50,51]. However,
there are deﬁned false-negative GM results in some speciﬁc
pediatric patients, such as those with chronic granulomatous
disease (CGD). One report details a non-neutropenic 4-
year-old child with CGD and IA diagnosed by lung biopsy
who had persistent false-negative serum GM testing [52].
Another study evaluated patients with CGD (n = 10) and
Job’s syndrome (n = 6) and IA, and found GM antigenaemia
in 4/15 cases of CGD and Job’s syndrome vs. 24/30 cases of
all other immunocompromised conditions (p 0.0004) (Walsh
et al., 40th IDSA, Abstract 345).
Testing in children with the newer assay for b-1,3-glucan
is very limited. Although clinical utility has been demon-
strated in adult patients, it is unclear, to date, whether paedi-
atric patients have a different baseline amount of glucan [53],
suggesting that more clinical trials need to be performed
before this exciting new test can best be used in paediatric
patients.
Paediatric and Neonatal Invasive Fungal
Infection Outcomes
In the large paediatric IA study, 57.3% of the paediatric
patients were treated with a lipid formulation of amphoteri-
cin B (mean 53.6 days), and voriconazole was given to 52.7%
of the patients for a mean of 184 days [20]. One-ﬁfth of
patients received one antifungal following the diagnosis of IA,
33.6% (44/131) received two antifungals concurrently, and
45.8% (60/131) received three or more concurrent antifun-
gals for at least 3 days following a diagnosis of IA. A total of
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52.5% of patients died during treatment for IA, and analysis
of mortality showed that allogeneic HSCT was a risk factor
for death; 78% of those undergoing allogeneic HSCT died at
12 weeks or at the end of therapy. Multivariate regression
analysis revealed that patients undergoing allogeneic HSCT
were six times more likely than other patients to die with IA
(OR 6.58; 95% CI 2.67–16.21).
Comparison of attributable outcome between adult and
paediatric candidaemia patients shows a higher number of
cases of candidaemia in children (43 vs. 30 cases per
100 000 admissions) [54]. In children, candidaemia resulted
in a 10.0% increase in mortality, a 21.1-day increase in length
of hospitalization, and a nearly $100 000 increase in hospital
costs. Risk factors for children with candidiasis include per-
sistent candidaemia (>3 days) with a central venous catheter
as well as immunosuppression [55].
Candida species have important ramiﬁcations, covered in
the recent treatment guidelines [56], as C. parapsilosis has
been shown to have reduced in vitro susceptibility to the echi-
nocandins, and C. glabrata has reduced susceptibility to ﬂuco-
nazole and voriconazole in multiple studies. The speciﬁc
clinically relevant issue of C. parapsilosis is not clear, as the
echinocandins clearly have efﬁcacy in most cases of C. parapsilosis
disease, but trials have shown decreased clinical efﬁcacy as
compared with infection with other Candida species [57].
One study suggested greater antifungal susceptibility at the
lower ages of patients, highlighting the fact that C. albicans and
C. parapsilosis are generally more susceptible, and this could
explain the overall trend. Fluconazole was also found to be
less active against C. glabrata isolates in children <1 year of
age, with only 63% of isolates being susceptible as compared
with isolates from patients aged 16–64 years (70% suscepti-
ble) and those over 65 years old (74% susceptible) [25].
The Future of Paediatric Invasive Fungal
Infection Epidemiology Investigation
Coordinated clinical and laboratory investigative efforts have
enhanced our understanding of the epidemiology of invasive
fungal infections and improved the treatment of adult
patients. However, most of these efforts have not incorpo-
rated children and neonates. Paediatric exclusion has limited
our knowledge of the epidemiology and pathophysiology of
paediatric fungal disease, and has resulted in a paucity of data
regarding the safety and efﬁcacy of paediatric antifungal ther-
apy. Previous paediatric cooperative models in other disci-
plines, including the Children’s Oncology Group and the
Pediatric AIDS Clinical Trials Group, have successfully
advanced our understanding and treatment of other child-
hood diseases. However, we are limited to extrapolation of
adult data for paediatric invasive fungal infections.
The multicentre International Pediatric Fungal Network
(PFN) (http://pfn.pediatrics.duke.edu) was created to gain a
complete understanding of the scope and epidemiology of
paediatric fungal infections, in order to improve the care of
our patients. The primary mission of the PFN is to increase
our knowledge of paediatric invasive fungal infections and
discern any undescribed characteristics or outcomes unique
to paediatric patients through a coordinated network of sci-
entiﬁc investigation. Large-scale epidemiological investigation
through a multicentre approach is what is required to fully
understand the details of paediatric invasive fungal infections.
In addition to advancing our understanding of the fundamen-
tal epidemiology of paediatric invasive fungal infections, the
PFN serves as an effective vehicle for investigators and
centres to conduct ground-breaking diagnostic and ther-
apeutic clinical trials focused on paediatric fungal infections,
diagnostic surrogates, and antifungals. The PFN is currently
collecting data never before obtained in children and neo-
nates, and the hope is that we will soon have a better under-
standing of the paediatric diseases and optimal diagnoses and
treatments for children.
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